Digestive and Liver Diseases

Overview

The Digestive & Liver Diseases research area is composed by three groups, whose main goal is to develop basic and traslational studies on the most frequent and impacting digestive and liver disorders afflicting the general population. In particular, the group of Physiology and Pathophysiology of the Digestive Tract integrates investigations on the function of the gastrointestinal tract including secretion, motility and absorption with cellular, molecular, immune and genetic aspects and their interactions with the microbiota and the brain-gut axis. The Liver Diseases Group deals clinical and basic research in viral hepatitis, liver cirrhosis, liver cancer and also non-alcoholic fatty liver disease and their complications. Finally, our area includes the Multidisciplinar Nursing research group which aims to generate knowledge in the specific area of activity of nurses and collaborate with other health professionals to improve care given to patients.

Publications

102

total

584.988

impact factor

5.735

average impact factor

Group Leader: Fernando Azpiroz Vidaur

team

group-zoom

zoom

group-download

download

In 2018 the group has continued the research program on digestive sensations in functional gut symptoms, by correlating physiological parameters with conscious sensations under different clinical and experimental conditions. Within this framework he role of microinflammation and gut microbiota has been addressed. Furthermore, the research program on the factors that determine the biological responses to food and diet has been expanded. A key aim of the program is the identification of innovative noninvasive biomarkers for the diagnosis, prevention and management functional gut disorders. To note, the group has maintained a high level of productivity (see publications), research funding (see research projects), networking (collaborative studies) and has attracted considerable mediatic interest in television, radio and press.

29

total

163^.795

impact factor

5^.648

average impact factor

SELECTED ARTICLES

Sangrador I, Molero X, Campbell F, Franch-Exposito S, Rovira-Rigau M, Samper E, Dominguez Fraile M, Fillat C, Castells A, Vaquero EC
Zeb1 in stromal myofibroblasts promotes Kras-driven development of pancreatic cancer.
Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-1882.
DOI: 10.1158/0008-5472.CAN-17-1882.
IF: 9,13
Keller J, Bassotti G, Clarke J, Dinning P, Fox M, Grover M, Hellstrom PM, Ke M, Layer P, Malagelada C, Parkman HP, Scott SM, Tack J, Simren M, Tornblom H, Camilleri M
Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders.
Nature Reviews Gastroenterology & Hepatology
Nat Rev Gastroenterol Hepatol. 2018 May;15(5):291-308.
DOI: 10.1038/nrgastro.2018.7. Epub 2018 Apr 6.
IF: 16,99
Rodino-Janeiro BK, Martinez C, Fortea M, Lobo B, Pigrau M, Nieto A, Gonzalez-Castro AM, Salvo-Romero E, Guagnozzi D, Pardo-Camacho C, Iribarren C, Azpiroz F, Alonso-Cotoner C, Santos J, Vicario M
Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction.
Sci Rep. 2018 Feb 2;8(1):2255
DOI: 10.1038/s41598-018-20540-9.
IF: 4,12
Gomez-Hurtado I, Gimenez P, Garcia I, Zapater P, Frances R, Gonzalez-Navajas JM, Manichahn C, Ramos JM, Bellot P, Guarner F, Such J
Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis.
Liver Int. 2018 Feb;38(2):295-302.
DOI: 10.1111/liv.13551. Epub 2017 Sep 13
IF: 4,5
Huaman JW, Mego M, Manichanh C, Canellas N, Canueto D, Segurola H, Jansana M, Malagelada C, Accarino A, Vulevic J, Tzortzis G, Gibson G, Saperas E, Guarner F, Azpiroz F
Effects of Prebiotics vs a Diet Low in Fodmaps in Patients with Functional Gut Disorder
Gastroenterology. 2018 Oct;155(4):1004-1007.
DOI: 10.1053/j.gastro.2018.06.045. Epub 2018 Jun 30.
IF: 20,773

View all publications